Stoke Therapeutics Inc. (STOK)
El precio, las cifras principales y las últimas noticias, en un solo sitio.
Stoke Therapeutics Inc. (STOK): cotización, análisis y datos
| Precio de compra | 31.54 |
| Capitalización de mercado | 2.03B |
| Ingresos (TTM) | 27.59M |
| Beneficio neto (TTM) | -207.9M |
| 1.23 | |
| -3.23 | |
| n/a | |
| -8.99 | |
| P/B (TTM) | 5.67 |
| P/S (TTM) | 73.44 |
| Fecha de resultados | Nov 3, 2026 |
| Precio de venta | 42.13 |
| Volumen | 1,485,489 |
| Volumen medio (20D) | 826,069 |
| Abierto | 32.48 |
| Anterior Cerrar | 33.03 |
| Rango del día | 29.87 - 32.59 |
| Rango de 52 semanas | 18.00 - 40.22 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de STOK
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy...
Desempeño financiero
En 2025, los ingresos de Stoke Therapeutics fueron 184.42M, un aumento de 404.5% en comparación con 36.55M del año anterior. Las ganancias fueron -6.88M, una disminución de -92.26%.
Estados financierosSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
2 semanas hace · Simply Wall St.
What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing?Stoke Therapeutics (NasdaqGS:STOK) filed a shelf registration for a potential 2,000,000 common share offering reportedly tied to an Employee Stock Ownership Plan. The filing indicates possible future ...
